1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
Novo Nordisk(NVO) The Motley Fool·2024-03-12 11:45Watch out, Novo Nordisk (NVO -1.38%) shareholders -- there's yet another new competitor on the scene that could one day unseat the likes of Ozempic and Wegovy as a leading treatment for type 2 diabetes and obesity. It's a next-gen weight loss pill being developed by a company you already know about: Novo Nordisk.That's right, according to the Danish pharma giant's presentation on Thursday at the Capital Markets Day 2024 event, it has a candidate in early clinical trials that preliminarily appears to be even ...